Celldex Therapeutics traded at $39.33 this Friday September 4th, decreasing $0.04 or 0.10 percent since the previous trading session. Looking back, over the last four weeks, Celldex Therapeutics lost 0.72 percent. Over the last 12 months, its price rose by 72.65 percent. Looking ahead, we forecast Celldex Therapeutics to be priced at 38.28 by the end of this quarter and at 35.88 in one year, according to Trading Economics global macro models projections and analysts expectations.
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutic monoclonal and bispecific antibodies. The Company's drug candidates include antibody-based therapeutics to improve the lives of patients with inflammatory diseases and many forms of cancer. The Company is engaged in the research and development of CDX-015, CDX-1140 and CDX-527. CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, has completed a Phase Ia study in healthy subjects. CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, is being studied in a Phase I study. CDX-527 is the first candidate from Celldex's bispecific antibody platform. CDX-527 is a bispecific antibody that uses the Company's anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, and Company has initiated a Phase I study in advanced solid tumors.